VAXXITEK®
HVT+IBD
A Lifetime of Immunity
HVT+IBD
Details
VAXXITEK® HVT+IBD is an innovative, safe, and effective vector vaccine that provides early protection against classic, variant, and very virulent pathotypes of IBD virus and Marek’s disease.1
-
VAXXITEK® HVT+IBD is an HVT-based vector vaccine
-
Contains the viral VP2 protein to stimulate IBD immunity
-
Systemic replication of the vector induces protection against 2 important diseases
Key Advantages
-
One single vaccination to protect against IBD and MD
-
Only one hatchery administration at day-old or in ovo
-
Early onset of immunity, no immunity gap2
-
Immune protection against classic, variant, and vvIBD from 14 days of age3
-
Onset of immunity against MD shown from 4 days of age3
-
Improved bursal health4
-
Up to 10 week duration of immunity5
-
Improved flock uniformity6
-
Controlling immunosuppression will reduce the need for antibiotics7
Features & Benefits
-
No interference with maternal antibodies5
-
Excellent primer and is effective in all types of poultry businesses – broiler, layer, and breeder chickens
-
HVT and VP2 will induce immune responses that protect against both IBD and MD4
-
VP2 elicits neutralizing antibodies
-
More than 70 scientific papers published to date8
-
100 billion birds vaccinated since first launch in 20069
Dosage & Administration
- Packaged in 5 x 2,000 and 5 x 4,000 dose ampules in frozen presentation
Resources
Safety
-
Do not mix with other products, except as specified on the label
-
In case of human exposure, contact a physician
-
Administer only as recommended
-
Use entire contents when first opened
-
Do not vaccinate within 21 days before slaughter
-
Contains penicillin and streptomycin sulfate which are added as bacteriostatic agents
-
Contains Amphotericin B as a fungistatic agent
-
Inactivate unused contents before disposal
Safety Data Sheet
1Rautenschlein S, Simon B, Jung A, Pöppel M, Prandini F, Lemiere S. Protective efficacy of VAXXITEK® HVT+IBD in commercial layers and broilers against challenge with very virulent infectious bursal disease virus. 16th Congress of the World Veterinary Poultry Association, Marrakesh, Morocco, 2009.
2Le Gros F-X, Dancer A, Giacomini C, Pizzoni L, Bublot M, Graziani M, Prandini F. Field efficacy trial of a novel HVT-IBD vector vaccine for 1-day-old broilers, Vaccine. 2009;27:592-596.
3Cruz-Coy J, Oliveira C, Pereira J, Ambrosino F, Gaudenci A, Le- Gros FX, Pritchard N. Efficacy of a Turkey Herpesvirus HVT-MDV serotype-3)-Infectious Bursal Disease (IBD) Vaccine, Live HVT Vector, IBD-VP2, Administered in ovo and to One-Day-Old SPF Chickens. Poster presentation. American Association of Avian Pathologists Convention, Hawaii, United States of America. 2006; p135.
4Bublot M. Vector vaccines for poultry: their advantages and limitations compared to classical vaccines. Proceedings of the International Symposium on Poultry Diseases, 14-15 December 2015.
5Bublot M, Prithcard N, Le Gros F-X, Goutebroze S. Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titered maternal derived antibody. Journal of Comparative Pathology, 2007;137:81-84.
6Garritty AT. The effect of vectored HVT+IBD (Vaxxitek® HVT+IBD) vaccination on body weights, uniformity and virus shedding in commercial broilers. Abstract. International Poultry Scientific Forum, Atlanta, 2011; p31.
7Lemiere S, Rojo R, He S, Tang S, Li W, Herrmann A, Prandini F. Benefits of the Herpesvirus of Turkey vector vaccine of Infectious Bursal Disease in control of immune depression in broilers and decrease of use of antibiotic medication. Abstract. XVIII Congress of the World Veterinary Poultry Association, Nantes, France, 2013.
8Data on file at Boehringer Ingelheim.
9Data on file at Boehringer Ingelheim.
VAXXITEK® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-POU-0056-2022